Physician profile
Sarah Seaton
NPI 1275086324
$1,502.09
in general payments reported to CMS, 2019-2025
25 companies · $925 in 2025
The $925 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $87.47 · 2023: $144 · 2024: $81.55 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.50 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $188.96 | 2025 | Auvelity |
| Abbvie INC. | $171.07 | 2024-2025 | |
| Globus Medical, INC. | $137.16 | 2021 | |
| Abbott Laboratories | $121.16 | 2023-2024 | Proclaim, Eterna |
| Alkermes, INC. | $85.00 | 2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $76.58 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Indivior INC. | $66.04 | 2025 | Sublocade |
| Lundbeck LLC | $54.64 | 2025 | Rexulti |
| Myovant Sciences INC. | $53.66 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $38.97 | 2021 | |
| Endo Pharmaceuticals INC. | $24.91 | 2021 | |
| Hologic Sales and Service, LLC | $24.30 | 2023 | Fluent Fluid Management System |
| Merck Sharp & Dohme LLC | $22.41 | 2022 | |
| Blue Earth Diagnostics | $22.00 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $21.25 | 2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $20.51 | 2025 | Belbuca |
| Janssen Biotech, INC. | $20.39 | 2022 | |
| Novo Nordisk INC | $17.38 | 2025 | |
| Convatec INC. | $16.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.42 | 2025 | Trintellix |
| Urovant Sciences INC | $15.14 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2024 | Uzedy |
| Lilly USA, LLC | $13.74 | 2025 | Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $13.01 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Seaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.